Simnotrelvir
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Simnotrelvir
- Molecular weight
- 536.6
- Structure (SMILES)
- COC[C@@H](NC(=O)C1CCCC(F)(F)C1)C(=O)N[C@H](Cc1ccccc1)C(=O)C(=O)NCc1nccs1
- simnotrelvir component of xiannuoxin
- Simnotrelvir component of xiannuoxin
- sim 0417
- SIM-0417
- sim0417
- Sim0417
- SIM0417
- simnotrelvir
- Simnotrelvir
- Simnotrelvir [WHO-DD]
- simnotrelvir who dd
- ssd 8432
- SSD-8432
- ssd8432
- SSD8432
- SSD8432 300mg
- SSD8432 750mg
- sy 110
- SY-110
- sy110
- SY110
- xiannuoxin component simnotrelvir
- XIANNUOXIN COMPONENT SIMNOTRELVIR
- ChEMBL ID
- CHEMBL5570561
- InChIKey
- IGYBDBUREWZAAX-OMKBGSMGSA-N
- PubChem compound IDs
- 167312484
- FDA ingredient codes (UNII)
- R4QFU2UR3K
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- SY110
- Type
- Synthetic organic
- Drug name stem
- -vir
Investigated indications
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
Trial references
- NCT05506176
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 3
- Polar surface area
- 126.49
- Calculated partition coefficient (ALogP)
- 2.01
- Calculated partition coefficient (XLogP)
- 2.4
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 12
- Heavy atoms
- 37
- Molecular formula
- C25H30F2N4O5S
- Monoisotopic mass
- 536.19049757
- Natural product
- No
- Recorded assays
- 3
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (8)
- A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
- A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects
- Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study
- Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir
- Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects
- Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants
- To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
- To Evaluate SSD8432/Ritonavir in Adults With COVID-19
In development for (1)
- COVID-19 Phase 2